Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Company’s Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.
종목 코드 PLSE
회사 이름Pulse Biosciences Inc
상장일May 18, 2016
CEOMr. Paul A. Laviolette
직원 수75
유형Ordinary Share
회계 연도 종료May 18
주소3957 Point Eden Way
도시HAYWARD
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호94545
전화15109064600
웹사이트https://www.pulsebiosciences.com/
종목 코드 PLSE
상장일May 18, 2016
CEOMr. Paul A. Laviolette
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음